TransMedics Group (NASDAQ:TMDX) Hits New 52-Week High at $132.96

TransMedics Group, Inc. (NASDAQ:TMDX) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $132.96 and last traded at $130.10, with a volume of 49462 shares trading hands. The stock had previously closed at $132.65.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TMDX. Piper Sandler reissued an “overweight” rating and set a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research note on Wednesday, May 1st. TD Cowen raised their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Morgan Stanley raised their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Finally, Canaccord Genuity Group raised their target price on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

TransMedics Group Stock Performance

The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. The stock has a market cap of $4.24 billion, a price-to-earnings ratio of -378.74 and a beta of 1.87. The stock’s 50-day moving average is $89.25 and its 200 day moving average is $79.26.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. The business had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company’s revenue was up 132.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.08) EPS. As a group, analysts predict that TransMedics Group, Inc. will post 0.62 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the completion of the sale, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,044,932.83. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Waleed H. Hassanein sold 12,000 shares of the company’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,044,932.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tamer I. Khayal sold 63,260 shares of TransMedics Group stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total value of $6,866,240.40. Following the completion of the sale, the insider now owns 9,792 shares of the company’s stock, valued at approximately $1,062,823.68. The disclosure for this sale can be found here. Insiders sold a total of 295,889 shares of company stock valued at $31,623,584 in the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in TransMedics Group by 1.7% during the third quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after acquiring an additional 29,798 shares during the last quarter. Moody Aldrich Partners LLC grew its stake in TransMedics Group by 110.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock worth $3,655,000 after buying an additional 24,290 shares during the period. American Century Companies Inc. increased its position in shares of TransMedics Group by 271.2% in the third quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock worth $26,661,000 after acquiring an additional 355,755 shares in the last quarter. Qube Research & Technologies Ltd raised its stake in shares of TransMedics Group by 31.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock valued at $4,624,000 after acquiring an additional 20,081 shares during the period. Finally, Sei Investments Co. increased its holdings in TransMedics Group by 17.8% in the 3rd quarter. Sei Investments Co. now owns 386,082 shares of the company’s stock valued at $21,139,000 after purchasing an additional 58,269 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.